Give Online: Help shape patient care for generations to come.


Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

CASE 2815 14-1222 Tissue and Body Fluid Analysis from Patients with Bladder Cancer and Other Urothelial Cancers of the Urinary Tract Main Campus  Bladder, Urothelial
MEDI 1816 16-1213 A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with MEDI4736 and MEDI0680 Monotherapy in Subjects with Select Advanced Malignancies Main CampusAdvanced/MetastaticPhase 1, Phase 2Bladder, Esophageal, GI (Gastrointestinal), Ovarian, Renal
MRK 3814 16-175 A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy Main Campus Phase 2Bladder
PFIZ 1816 16-397 A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab* (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy Main Campus Phase 3Bladder, Urothelial
ROCH 1815 15-1059 A Phase III, open-label, multicenter, randomized study of atezolizumab (Anti-PD-L1 antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high-risk muscle-invasive bladder cancer after cystectomy Fairview, Hillcrest, Main Campus Phase 3Bladder
SWOG 131414-1443 A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster Phase 2Bladder
UAB 1815 15-980 A Multicenter, Non-Randomized, Phase II study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy Main Campus  Bladder

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.